BLFS 📈 BioLife Solutions - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062W2044

BLFS: Biopreservation Media, Bioproduction Tools, Cryogenic Freezers, Storage Containers

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington. Web URL: https://www.biolifesolutions.com

Additional Sources for BLFS Stock

BLFS Stock Overview

Market Cap in USD 1,217m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Supplies
IPO / Inception 1989-11-22

BLFS Stock Ratings

Growth 5y 27.4%
Fundamental -22.1%
Dividend -
Rel. Strength Industry 1196
Analysts 4.8/5
Fair Price Momentum 26.20 USD
Fair Price DCF 2.37 USD

BLFS Dividends

No Dividends Paid

BLFS Growth Ratios

Growth Correlation 3m 65%
Growth Correlation 12m 89.1%
Growth Correlation 5y -15.9%
CAGR 5y 10.96%
CAGR/Mean DD 5y 0.24
Sharpe Ratio 12m 1.08
Alpha 19.16
Beta 1.63
Volatility 63.30%
Current Volume 125.3k
Average Volume 20d 325.2k
What is the price of BLFS stocks?
As of December 28, 2024, the stock is trading at USD 27.03 with a total of 125,285 shares traded.
Over the past week, the price has changed by +3.52%, over one month by -0.11%, over three months by +11.83% and over the past year by +62.24%.
Is BioLife Solutions a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, BioLife Solutions is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -22.09 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BLFS as of December 2024 is 26.20. This means that BLFS is currently overvalued and has a potential downside of -3.07%.
Is BLFS a buy, sell or hold?
BioLife Solutions has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy BLFS.
  • Strong Buy: 8
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BLFS stock price target?
According to ValueRays Forecast Model, BLFS BioLife Solutions will be worth about 29.7 in December 2025. The stock is currently trading at 27.03. This means that the stock has a potential upside of +9.69%.
Issuer Forecast Upside
Wallstreet Target Price 29.8 10.2%
Analysts Target Price 24.4 -9.6%
ValueRay Target Price 29.7 9.7%